Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antineutrophil Cytoplasmic Antibody
100%
Renal Disease
100%
Large Vessel Vasculitis
100%
Estimated Glomerular Filtration Rate
100%
Rituximab
100%
Remission
75%
End-stage Renal Disease
75%
Cyclophosphamide
50%
Dialysis
50%
6-month Follow-up
50%
ANCA-associated Vasculitis
50%
Remission Induction
50%
Glucocorticoid Therapy
50%
Dialysis Independence
50%
AIMS™
25%
Inclusion Criteria
25%
Safety Profile
25%
Adverse Events
25%
Vasculitis
25%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
25%
Survival Rate
25%
Relapsed Disease
25%
Working Diagnosis
25%
Time to Remission
25%
Severe Renal Impairment
25%
Median Time
25%
Renal Function
25%
New Disease
25%
Disease Survival
25%
Rituximab Therapy
25%
Antibody-negative
25%
Plasmapheresis
25%
Multicenter Retrospective Cohort Study
25%
Outcome Profiles
25%
Medicine and Dentistry
Nephropathy
100%
Neutrophil Cytoplasmic Antibody
100%
Glucocorticoid
100%
Small Vessel Vasculitis
100%
Rituximab
100%
Glomerular Filtration Rate
80%
End Stage Renal Disease
60%
ANCA Associated Vasculitis
60%
Cyclophosphamide
40%
Vasculitis
20%
Survival Rate
20%
Recurrent Disease
20%
Adverse Event
20%
Kidney Function
20%
Severe Renal Impairment
20%
Retrospective Cohort Study
20%
Plasmapheresis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neutrophil Cytoplasmic Antibody
100%
Remission
100%
Kidney Disease
100%
Small Vessel Vasculitis
100%
Rituximab
100%
Glucocorticoid
83%
End Stage Renal Disease
50%
ANCA Associated Vasculitis
50%
Cyclophosphamide
33%
Cohort Study
16%
Adverse Event
16%
Recurrent Disease
16%
Survival Rate
16%
Vasculitis
16%
Severe Renal Impairment
16%
Neuroscience
Neutrophil Cytoplasmic Antibody
100%
Glucocorticoid
100%
Rituximab
100%
Cyclophosphamide
40%